Year Founded
1990
Ownership
Public
Employees
~50
Therapeutic Areas
OncologyOphthalmologyGastroenterologyNeurologyMetabolic DisordersDermatology
Stage
Commercial
Modalities
Small moleculeOtherMedical devices

APR Applied Pharma Research General Information

APR Applied Pharma Research has developed and commercialized innovative products for rare and niche therapeutic areas. Clinical results for Nexodyn® AOS demonstrate superior wound healing performance compared to standard care, with significant reductions in wound size and infection rates.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Balerna, Ticino
Switzerland

Drug Pipeline

PKU GOLIKE
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to APR Applied Pharma Research's pipeline data

Book a demo

Key Partnerships

Relief Therapeutics Holding AG, HBM Partners, Bright Technology Fund

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

APR Applied Pharma Research Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view APR Applied Pharma Research's complete valuation and funding history, request access »